Department of Critical Care Medicine, The First Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Graduate School of The People's Liberation Army (PLA) General Hospital, Beijing, China.
Front Immunol. 2024 May 21;15:1391395. doi: 10.3389/fimmu.2024.1391395. eCollection 2024.
Sepsis is a clinical syndrome caused by uncontrollable immune dysregulation triggered by pathogen infection, characterized by high incidence, mortality rates, and disease burden. Current treatments primarily focus on symptomatic relief, lacking specific therapeutic interventions. The core mechanism of sepsis is believed to be an imbalance in the host's immune response, characterized by early excessive inflammation followed by late immune suppression, triggered by pathogen invasion. This suggests that we can develop immunotherapeutic treatment strategies by targeting and modulating the components and immunological functions of the host's innate and adaptive immune systems. Therefore, this paper reviews the mechanisms of immune dysregulation in sepsis and, based on this foundation, discusses the current state of immunotherapy applications in sepsis animal models and clinical trials.
脓毒症是一种临床综合征,由病原体感染引发的失控免疫失调引起,其具有发病率高、死亡率高和疾病负担重的特点。目前的治疗方法主要侧重于对症缓解,缺乏特异性的治疗干预。脓毒症的核心机制被认为是宿主免疫反应的失衡,其特征是病原体入侵后早期过度炎症,随后晚期免疫抑制。这表明,我们可以通过针对宿主固有和适应性免疫系统的成分和免疫功能,开发免疫治疗策略。因此,本文综述了脓毒症中免疫失调的机制,并在此基础上讨论了免疫疗法在脓毒症动物模型和临床试验中的应用现状。